文献速递骨软组织肉瘤与黑色素瘤

AJCC第八版黑色素瘤分期:基于证据的更新

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
PubMed 文献 · CA Cancer J Clin · 2017-10-13

AJCC黑色素瘤专家小组基于全球10个中心逾46000例I–III期患者数据库、第七版IV期数据库及当代临床试验数据,对TNM分类与分期分组标准作出修订。第八版主要变更包括肿瘤厚度记录精度、T1a/T1b定义、病理IA期纳入T1bN0M0、N类别描述语重定义、III期预后分组增至4个亚组、N亚类定义修订、M1各亚类加入LDH描述语及新增M1d中枢神经系统转移。

要点

  • 肿瘤厚度记录至0.1 mm(非0.01 mm),核分裂率不再是T类别标准。
  • 病理IA期修订为包含T1b N0 M0(原病理IB期)。
  • III期预后分组增至IIIA–IIID共4个亚组,基于N与T类别标准。

核心结论

  • 第八版AJCC黑色素瘤分期系统为基于证据的修订,旨在指导患者治疗、提供更好的预后估计并细化临床试验患者分层。

研究设计与样本

  • AJCC黑色素瘤专家小组汇集全球10个中心逾46000例自1998年以来诊断的I、II、III期黑色素瘤患者数据库,并结合第七版IV期数据库及当代临床试验数据进行分析。

主要发现

  • 肿瘤厚度测量改为记录至最接近的0.1 mm而非0.01 mm。
  • T1a定义为<0.8 mm无溃疡,T1b定义为0.8-1.0 mm伴或不伴溃疡或<0.8 mm伴溃疡,核分裂率不再作为T类别标准。
  • 病理IA期修订为包含T1b N0 M0(原为病理IB期)。
  • III期预后分组基于N类别与T类别(原发肿瘤厚度和溃疡)标准,由3个增至4个亚组(IIIA–IIID)。
  • M1各亚类新增LDH水平描述语(LDH升高不再上调至M1c),并新增M1d用于中枢神经系统转移。

关键数值与推荐

  • 肿瘤厚度记录至最接近的0.1 mm,不是0.01 mm。
  • T1a:<0.8 mm无溃疡;T1b:0.8-1.0 mm伴或不伴溃疡,或<0.8 mm伴溃疡。
  • 病理IA期包含T1b N0 M0(原病理IB期);临床IA期未作此修订。
  • 区域淋巴结转移的N类别描述语「microscopic」和「macroscopic」重定义为「clinically occult」和「clinically apparent」。
  • 微卫星灶、卫星灶或途中转移按累及区域淋巴结数目归为N1c、N2c或N3c。

临床怎么用

  • 依据第八版AJCC黑色素瘤分期标准进行TNM分类与分期分组,以指导患者治疗、预后估计及临床试验分层。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors "microscopic" and "macroscopic" for regional node metastasis are redefined as "clinically occult" and "clinically apparent"; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017. PMID: 29028110. doi:10.3322/caac.21409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。